Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes

European Journal of Clinical Pharmacology

Volumn 56, Issue 9-10, 2000, Pages 711-714

  Jönsson, Anders ^a   Chan, Juliana C N ^b,c   Rydberg, Tony ^d   Vaaler, Stein ^e   Hallengren, Bengt ^a   Cockram, Clive S ^c   Critchley, Julian A J H ^c   Melander, Arne ^f  

^a LUND UNIVERSITY   (Sweden)

^b RYHOV COUNTY HOSPITAL   (Sweden)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d The Pharmacies in Skane   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f Network for Pharmacoepidemiology Foundation   (Sweden)

Author keywords

Pharmacokinetics; Proinsulin; Sulphonylurea

Indexed keywords

GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; INSULIN; MINDIAB; PLACEBO; PROINSULIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; ETHNOLOGY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLIPIZIDE; GLUCOSE TOLERANCE TEST; GLYBURIDE; HALF-LIFE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROINSULIN;

EID: 0034467568     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000214     Document Type: Article

References (19)

1. Overview of non-insulin dependent diabetes mellitus (NIDDM) in different population groups
2. Diabetes mellitus in Chinese and its implications on health care
3. UK Prospective Diabetes Study XII: Differences between Asian, Afro-Caribbean and white Caucasian type 2 diabetic patients at diagnosis of diabetes
4. Ethnic differences in drug disposition and responsiveness
5. Synthesis of putative metabolites and investigation of the metabolic rate of gliclazide in diabetic patients
6. Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type 2 diabetes
7. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance
8. Insulin deficiency in noninsulin-dependent diabetes
9. Preferential release of proinsulin relative to insulin in non-insulin-dependent diabetes mellitus
10. Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus
11. Elevated ratio of summed serum proinsulin to insulin response after oral glucose load in type 2 diabetes decreases following sulfonylurea treatment
12. Hyperproinsulinemia of type 2 diabetes is not present prior to the development of hyperglycemia
13. Effects of conventional and intensified insulin therapy on free-insulin profiles and glycemic control in NIDDM
14. Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography
15. High-performance liquid chromotagraphic determination of glipizide and some other sulfonylurea drugs in serum
16. Interindividual variation in the absorption of glibenclamide in man
17. Absorption of glibenclamide from different sites of the gastro-intestinal tract
18. Pharmacokinetics and metabolism of gliclazide: A review
19. The etabolism of gliclazide in man